Previous 10 | Next 10 |
2024-06-21 16:51:47 ET Summary Schwab U.S. Dividend Equity ETF™ is a conservative fund that offers stable growth and dividend growth, not suitable for high-growth or high-yield investors. It is too boring for you. The SCHD ETF holds 103 diversified holdings, with the top se...
2024-06-20 23:47:38 ET Summary Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly boost Nektar's prospects (and share price), but Phas...
2024-06-20 09:00:00 ET Summary This week, I added to my positions in CSCO, PFE, and UTF. In the 2nd week of June, the Dividend Harvesting Portfolio generated $21.73 of dividend income. The Dividend Harvesting Portfolio has already generated 65.31% of the total dividend income ...
2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the w...
2024-06-18 15:03:18 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...
2024-06-18 14:13:37 ET More on Pfizer Pfizer Stock: The Reversal Should Keep Going Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcrip...
2024-06-18 13:13:38 ET More on Day One Biopharmaceuticals Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M Day One slips despite Ojemda approval as BofA says labe...
2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...
2024-06-18 10:00:00 ET When it comes to investing in high-yield dividend stocks in the pharmaceutical space, two prominent names often come to mind: Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) . Both companies have a long history of paying dividends and offer...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...